Barale C, Bonomo K, Frascaroli C, et al. - In order to confirm if platelet function in primary hypercholesterolemia (HC) is influenced by a treatment up to 12 months with the monoclonal antibodies (mAbs) anti-PCSK9 (proprotein convertase subtilisin/kexin type 9), researchers undertook this investigation in 24 patients with primary HC, all on background of statin and 17 on acetyl salicylic acid. At baseline and up to 12 months of therapy with alirocumab or evolocumab, the evaluation of platelet function parameters was performed in the participants. PCSK9 mAb treatment in HC patients resulted in a marked lowering of LDL-c levels, as well as had benefits for attenuating platelet reactivity and improving platelet sensitivity to the inhibitory influences of aspirin. These influences on platelets could be implicated in the attenuation of cardiovascular event incidence in patients treated with PCSK9-inhibitors.